GlassScriptPhysician profile
Phillip D Barnes
NPI 1538392691
$3,665.93
in general payments reported to CMS, 2019-2025
37 companies · $387 in 2025
The $387 reported for 2025 was more than what a typical Physician Assistant provider received nationally (typical 2025 total: $183).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $1,096 · 2022: $941 · 2023: $644 · 2024: $597 · 2025: $387.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,628.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,628.06 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $850.13 | 2021-2025 | |
| Astrazeneca Pharmaceuticals LP | $557.56 | 2021-2025 | Airsupra, Breztri, Farxiga |
| Amgen INC. | $396.09 | 2021-2025 | Repatha, Otezla, Evenity |
| Lilly USA, LLC | $364.80 | 2021-2025 | Jardiance, Zepbound, Mounjaro |
| Glaxosmithkline, LLC. | $169.61 | 2021-2025 | Trelegy Ellipta, Bexsero |
| Novo Nordisk INC | $144.36 | 2021-2024 | Ozempic, Rybelsus |
| Otsuka America Pharmaceutical, INC. | $126.52 | 2022-2025 | Rexulti, Abilify Maintena |
| Sanofi-Aventis U.S. LLC | $122.21 | 2021-2022 | |
| Pfizer INC. | $108.46 | 2021-2025 | |
| Dexcom, INC. | $98.58 | 2021-2025 | Dexcom G6 Transmitter |
| Janssen Pharmaceuticals, INC | $61.54 | 2021-2022 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $57.09 | 2022 | |
| Abbott Laboratories | $51.55 | 2021-2023 | Nc Trek Neo |
| Sumitomo Pharma America, INC. | $41.46 | 2025 | Gemtesa |
| Bayer Healthcare Pharmaceuticals INC. | $39.28 | 2021-2024 |
Show all 37 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Eisai INC. | $33.55 | 2021 | |
| Nevro Corp. | $31.98 | 2022 | |
| Novartis Pharmaceuticals Corporation | $31.55 | 2024-2025 | |
| Takeda Pharmaceuticals U.S.A., INC. | $30.39 | 2021-2022 | |
| Genzyme Corporation | $28.62 | 2023 | |
| Biohaven Pharmaceutical Holding Company LTD. | $28.09 | 2022 | |
| Ucb, INC. | $27.65 | 2022 | |
| Organon LLC | $27.13 | 2022 | |
| Edwards Lifesciences Corporation | $23.67 | 2025 | Sapien 3 Ultra Resilia |
| Sunovion Pharmaceuticals INC. | $22.93 | 2021 | |
| Alexion Pharmaceuticals, INC. | $19.56 | 2025 | Strensiq |
| Ferring Pharmaceuticals INC. | $18.91 | 2023 | Rebyota |
| Insulet Corporation | $18.78 | 2024 | Omnipod |
| Mylan Specialty L.P. | $18.72 | 2024 | Yupelri |
| Phathom Pharmaceuticals, INC. | $18.71 | 2025 | Voquezna |
| Kyowa Kirin, INC. | $16.91 | 2024 | Crysvita |
| Idorsia Pharmaceuticals US INC | $14.46 | 2023 | Quviviq |
| Viatris Specialty LLC | $14.02 | 2025 | Yupelri |
| Janssen Biotech, INC. | $13.64 | 2022 | |
| Nestle Healthcare Nutrition INC. | $13.00 | 2021 | |
| Xeris Pharmaceuticals, INC. | $12.46 | 2021 | |
| Merck Sharp & Dohme LLC | $11.96 | 2021 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Phillip Barnes listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.